Kenya Class C and D Registration Routes: Full, Abridged, ECR and EDR

Content verified as of October 30, 2026

1. Key takeaways

• Class C and Class D offer only three routes: full evaluation (Full), abridged evaluation (Abridged) and expedited evaluation (Expedited, with the ECR and EDR sub-routes).
• Abridged requires approvals for the same labeled use from at least 3 reference regulatory agencies (RRAs), one more than the at least 2 required for Class B.
• ECR has two gates: at least 3 RRA approvals plus marketing for at least 5 years with no safety issues in the past 3 years; or at least 5 RRA approvals.
• EDR has the lowest approval-count threshold, at least 2 RRA approvals, but the strictest exclusion list.
• ECR excludes non-bioactive implants for hip, knee and shoulder replacement (Full or Abridged only); EDR excludes four categories of devices.
• Fees: Class C and Class D import registration USD 1,000 each, annual retention USD 300; expedited review costs USD 2,000 extra.

2. Legal basis

3. Expert insights

Insight 1: The three routes layer along self-proof, reliance, and reliance plus maturity

Full wins on the completeness of the applicant’s own dossier; Abridged swaps the review foundation for approvals of the same labeled use from at least 3 RRAs; Expedited layers maturity requirements on top of reliance. Set against the Class B conditions, the progression becomes visible: the Class B expedited route requires at least 2 approvals plus 3 years on the market, while Class C/D ECR requires at least 3 approvals plus 5 years. The higher the class, the less PPB asks for more documents and the more it asks for a longer history of real-world use, because the long-term safety of high-risk devices cannot be derived from documents alone.

Insight 2: The ECR OR structure creates two entirely different gates

The first ECR gate is at least 3 RRAs, at least 5 years on the market and no safety issues in the past 3 years; the second gate is at least 5 RRAs, with no marketing-history requirement, in substance substituting approval count for time evidence. GRZAN’s assessment: for a mature product with a broad global footprint, assembling 5 approvals is often faster than waiting out 5 years; for a product long sold in major markets whose reference approvals concentrate in two or three authorities, the first gate is more realistic. Mixing the gates, partly satisfying 3 approvals and partly satisfying 5 years, does not work.

Insight 3: The exclusion lists encode the idea that reliance cannot replace local judgment

ECR excludes non-bioactive implants for hip, knee and shoulder replacement; such devices may proceed only through Full or Abridged. EDR excludes four categories: active implantable devices (pacemakers, neurostimulators); implantable devices in direct contact with the central circulatory system or the central nervous system; hip, knee and shoulder replacement with bioactive implants; and devices containing a registrable medicine for an ancillary action. What the three orthopedic categories and the vascular and neural implants share is irreversibility and an extremely costly revision, and PPB declines to substitute foreign conclusions for local judgment. Drug-device combinations are excluded for a further reason: they require joint review by the medical devices directorate and the biologics and human medicines directorate, which a reliance route cannot carry.

Insight 4: The cost of switching routes shows up as a double loss in fees and records

The fee rules are: the application fee is paid at submission and the evaluation fee when the application is accepted for evaluation; the application fee is non-refundable once successfully submitted, the evaluation fee is forfeited once accepted, and both are forfeited on withdrawal or rejection. Taking the wrong route therefore costs more than rescheduling: an application fee at the USD 1,000 level cannot be recovered, and a rejected application remains on record at PPB. On timelines, the current guidelines do not state specific days in text; the first edition of the submission guidelines expressed it as 90 calendar days. As a practical estimate, GRZAN advises that the route decision be finalized before submission, because after submission a route change can only take the form of withdrawal or rejection.

4. Practical recommendations

1. Clear the exclusion lists before discussing routes. Products matching an ECR or EDR exclusion should be prepared directly for Full or Abridged.
2. Count RRA approvals and time evidence. Check both ECR gates separately: 3 approvals plus 5 years, or 5 approvals.
3. Prepare drug-device combinations for joint review. Fix the PMOA conclusion and the Class D classification before scheduling.
4. Build the marketing history as a timeline. Support the 5-year requirement with first commercial sale records, not registration certificate dates.
5. Move the route decision before submission. Weigh the fee losses from withdrawal and rejection; avoid switching routes mid-review.
6. Budget at the top tier. Put USD 1,000 registration, USD 300 annual retention and USD 2,000 expedited review into the same calculation.

5. Verification checklist

• □ Have the ECR and EDR exclusion lists been checked and the product confirmed not excluded?
• □ Has the count of RRA approvals been tallied (2, 3 or 5)?
• □ Can the marketing-history evidence support 5 years, based on commercial sale records rather than only registration certificate dates?
• □ Is there traceable evidence of no safety issues in the past 3 years?
• □ For drug-device combinations, has the PMOA assessment been completed and joint review arranged?
• □ Has the cost of switching routes been assessed (non-refundable application fee, forfeited evaluation fee)?
• □ Does the budget include USD 1,000 registration, USD 300 annual retention and USD 2,000 expedited review?
• □ Does the schedule avoid applying 90 calendar days directly (practical estimate)?

Regulatory information verified as of October 30, 2026.

Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.

GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.

For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.